The use of 3D printing prior to transaortic valve replacement (TAVR) procedures may help cardiac surgeons to predict areas where an ill-fitting stent frame could lead to paravalvular leaks (PVLs), a small retrospective study has shown.
Neither intravenous (IV) sodium bicarbonate nor oral N-acetylcysteine (NAC) is better than IV saline in reducing 90-day events or contrast-associated acute kidney injury (AKI) in the PRESERVE substudy, suggesting that normal saline hydration is the default therapy for contrast-induced AKI.
The hybrid approach to percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) yielded good success rates in the hands of experienced operators, the PROGRESS CTO* Registry study has shown, offering important benchmarking for discussion of the risk-benefit ratio of CTO PCI.
Transcatheter mitral valve repair with the MitraClip device significantly improves the severity of mitral regurgitation (MR), functional status, and quality of life of patients with MR and who were at prohibitive risk for surgery, according to the MitraClip Post-Approval Study 1 (PAS1) presented at SCAI 2018.
Biologic therapy for treating psoriasis, in particular anti-TNF agents, can also help reduce coronary plaque besides suppressing inflammation in the skin, suggests a study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions in San Diego, California, US.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).